Top Stories
Top Stories
Press Releases

Immunomic Therapeutics to Present at 15th Annual World Vaccine Congress

Globe Newswire

HERSHEY, Pa. and ROCKVILLE, Md., April 2, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ( "ITI") a privately-held biotechnology company pioneering next-generation vaccines based on its proprietary LAMP technology, today announces it will be presenting at the 15th Annual World Vaccine Congress, which will be held at the Walter E. Washington Convention Center in Washington, D.C. on April 7-9, 2015. The company will be presenting on April 8th, and will be exhibiting at booth #16.

ITI's presentations will be at the following times:
Title: Nucleic Acid Vaccines for Oncology incorporating LAMP-Vax Technology
Presenter: Dr. Duane Mitchell, University of Florida
Time: 3:40 pm (EDT)

Title: DNA Vaccines for animal health utilizing LAMP-Vax Technology
Presenter: Dr. Teri J. Heiland, VP, R&D
Time: 5:10 pm (EDT)

"This is an important conference for ITI as it gathers the top thinkers from the world of vaccines together to discuss new strategies and approaches to vaccination, as well as new areas where vaccines are beginning to be explored," said William Hearl, Ph.D., CEO of Immunomic Therapeutics, Inc. "Our LAMP-vax technology has numerous applications and we are looking forward to sharing our progress with our colleagues while expanding our relationships with potential partners and collaborators."

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies Currently, the company is pursuing three main allergy programs:

  • ASP 4070 (Formerly known as JRC-LAMP-Vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
    • An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
  • ARA-LAMP-Vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
  • Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.

For more information about ITI and LAMP Technology, please visit

CONTACT: Jules Abraham JQA Partners, Inc. (917) 885-7378 Sia Anagnostou Immunomic Therapeutics, Inc (717) 327-1822Source:Immunomic Therapeutics, Inc.

Related Tags